Nile Therapeutics Announces Upcoming Data Presentation at the American College of Cardiology Annual Scientific Meeting

Mar 30, 2011, 07:00 ET from Nile Therapeutics, Inc.

SAN MATEO, Calif., March 30, 2011 /PRNewswire/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced the schedule of its upcoming cenderitide presentation taking place at the American College of Cardiology (ACC) 60th Scientific Session, April 2-5th.

Location: Ernest N. Morial Convention Center, Hall F Date: Sunday, April 3, 2011 Time: 10:00 AM -11:15 AM (CDT) Poster Presentation: Board #256 Presenter: Hsiao D. Lieu, MD, FACC Title: "A Phase II, Dose-Ranging Study with CD-NP, a Chimeric Natriuretic Peptide, in Acute Decompensated Heart Failure Patients with Renal Compromise"

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical needs. Nile is initially focusing its efforts on developing its lead compound, cenderitide, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure, and CU-NP, a novel rationally designed natriuretic peptide. More information on Nile can be found at http://www.nilethera.com.

SOURCE Nile Therapeutics, Inc.



RELATED LINKS

http://www.nilethera.com